Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527975) titled 'Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102' on April 7.

Study Type: Observational

Primary Sponsor: Rocket Pharmaceuticals Inc.

Condition: Fanconi Anemia

Intervention: Biological: RP-L102

Recruitment Status: Recruiting

Date of First Enrollment: February 1, 2022

Target Sample Size: 14

Countries of Recruitment: United States Spain United Kingdom Spain United Kingdom United States

To know more, visit https://clinicaltrials.gov/study/NCT07527975

Disclaimer: Curated by HT Syndication....